10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC lowered its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 17.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,651 shares of the company’s stock after selling 2,667 shares during the period. Axxcess Wealth Management LLC’s holdings in 10x Genomics were worth $182,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Signaturefd LLC grew its position in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the period. Blue Trust Inc. raised its stake in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC lifted its holdings in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after buying an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in 10x Genomics during the 4th quarter worth $52,000. Finally, First Horizon Advisors Inc. grew its stake in 10x Genomics by 53.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after purchasing an additional 1,012 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

TXG has been the subject of several research reports. Morgan Stanley reduced their target price on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $25.00 to $12.00 in a report on Thursday, February 13th. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Citigroup cut their target price on 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.21.

Insider Activity

In other news, Director Alan Mateo bought 40,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the acquisition, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Stock Up 4.4 %

Shares of NASDAQ TXG opened at $10.39 on Friday. The firm’s 50-day moving average price is $12.68 and its two-hundred day moving average price is $15.53. The stock has a market capitalization of $1.27 billion, a P/E ratio of -6.84 and a beta of 1.93. 10x Genomics, Inc. has a 52-week low of $9.27 and a 52-week high of $38.49.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.